Eli Lilly's portfolio is in the middle of a big shift, with newer diabetes drugs taking the reins of that franchise and its blockbuster erectile dysfunction drug Cialis, already suffering from copycat Viagra competition, on its way to a generics battle this fall. But the drugmaker was confident enough in 2018 to hike its guidance.Original Article
The Viagra effect: Sales of Lilly’s ED drug Cialis slide after little blue pill goes generic
